OncoMatch/Clinical Trials/NCT06237920
Stage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without Relatlimab
Is NCT06237920 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Nivolumab and Relatlimab for urologic neoplasms.
Treatment: Nivolumab · Relatlimab — This is a non-blinded phase 2 trial in Stage II-IIIa urothelial cancer randomizing pre-operative nivolumab with or without relatlimab to assess whether bladder preservation after dual immunotherapy would be a viable treatment option for patients responding to treatment
Check if I qualifyExtracted eligibility criteria
Cancer type
Urothelial Carcinoma
Disease stage
Required: Stage CT2-4AN0M0, CT1-4AN1M0
Performance status
WHO 0–1
Prior therapy
Cannot have received: intravenous systemic therapy
Previous intravenous systemic therapy or radiotherapy for UC
Cannot have received: radiotherapy
Previous intravenous systemic therapy or radiotherapy for UC
Cannot have received: CTLA-4 inhibitor
Prior CTLA-4, LAG3 or PD-1/PD-L1-targeting immunotherapy
Cannot have received: LAG3 inhibitor
Prior CTLA-4, LAG3 or PD-1/PD-L1-targeting immunotherapy
Cannot have received: anti-PD-1 therapy
Prior CTLA-4, LAG3 or PD-1/PD-L1-targeting immunotherapy
Cannot have received: anti-PD-L1 therapy
Prior CTLA-4, LAG3 or PD-1/PD-L1-targeting immunotherapy
Lab requirements
Blood counts
WBC ≥ 2.0x10^9/L, Platelets ≥100 x10^9/L, Hemoglobin ≥5.5 mmol/L
Kidney function
GFR >30 ml/min
Liver function
AST ≤ 1.5 x ULN, ALT ≤1.5 x ULN, Bilirubin ≤1.5 X ULN
Screening laboratory values must meet the following criteria: WBC ≥ 2.0x109/L, Platelets ≥100 x109/L, Hemoglobin ≥5.5 mmol/L, GFR>30 ml/min, AST ≤ 1.5 x ULN, ALT ≤1.5 x ULN, Bilirubin ≤1.5 X ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify